title: Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis.
abstract: In a double-masked, randomized fashion, 11 patients with hematologic malignancies received 13 courses of high-dose cytarabine therapy, intravenously (3 g/m2 every 12 hours for five to six days). Each patient received topical prednisolone phosphate 1% in one eye and 2-deoxycytidine 100 microM in the other eye every six hours. Topical therapy was initiated 12 hours before the first cytarabine dose and continued for up to ten days (until four to five days after completion of cytarabine therapy). Slit-lamp biomicroscopy was performed before therapy and then weekly for one month. 2-Deoxycytidine was equally as effective as the topical corticosteroid therapy in reducing photophobia and pain, microcysts, and punctate epithelial erosions, and each treatment gave results significantly better when compared historically to placebo-treated eyes.
authors.affiliation: Department of Medicine, University Hospitals of Cleveland, OH 44106.
authors.forename: H M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: M E
authors.initials: ME
authors.lastname: Hartnett
authors.forename: M D
authors.initials: MD
authors.lastname: Reed
authors.forename: B F
authors.initials: BF
authors.lastname: Murphy
authors.forename: J H
authors.initials: JH
authors.lastname: Lass
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000818:Animals; D002986:Clinical Trials as Topic; D003315:Cornea / Q000187:drug effects / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007634:Keratitis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D011897:Random Allocation
chemical_list: D003561:Cytarabine; D003841:Deoxycytidine; D011239:Prednisolone